Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company.
There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.
I won’t be able to comment on specific products. We do expect this along with other applications that are pending and once we have the product approval, we will be able to talk about it in much more detail, he said.
Won’t comment on speculations, he added.
He further said that he feels encouraged of the solid pipeline of products that the company will bring to market this year. “We remain quite bullish about our performance overall in FY18,” he added.
Speaking about Australia business, he said, the business is going well. Australian market is a consolidated market and top four players account for about 85 percent of the total market. The company is one of the leading players in Australia.
For full interview, watch accompanying video...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
